Complete caloric recovery · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)
Corticosteroids may leads to higher complete caloric recovery compared with placebo (low certainty).
2 findings from 1 review
Adverse effects · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)
1 finding from 1 review
Change in hearing threshold determined by PTA Range 0 dB to 140 dB Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement. Â · sudden sensorineural hearing loss
Intratympanic plus systemic corticosteroids (combined therapy) showed no clear difference in change in hearing threshold determined by PTA Range 0 dB to 140 dB… compared with systemic corticosteroids alone (low certainty).
2 findings from 1 review
Proportion of patients whose hearing is improved · sudden sensorineural hearing loss
It is very uncertain whether intratympanic plus systemic corticosteroids (combined therapy) changes proportion of patients whose hearing is improved compared with systemic corticosteroids alone (very low certainty).
2 findings from 1 review
Final hearing threshold determined by PTA (a lower value represents better hearing) · sudden sensorineural hearing loss
It is very uncertain whether intratympanic plus systemic corticosteroids (combined therapy) changes final hearing threshold determined by PTA A lower value represents… compared with systemic corticosteroids alone (very low certainty).
2 findings from 1 review
Adverse eventsb · sudden sensorineural hearing loss
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Persistent tympanic membrane perforation · sudden sensorineural hearing loss
2 findings from 1 review
Vertigo/dizziness: timing not reported · sudden sensorineural hearing loss
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Vertigo/dizziness: at the time of injection · sudden sensorineural hearing loss
2 findings from 1 review
Ear pain: timing not reported · sudden sensorineural hearing loss
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Ear pain: at the time of injection · sudden sensorineural hearing loss
2 findings from 1 review
Disease severity as measured by patient‐reported symptom score (total nasal symptom score) · adults and children > 12 with non‐allergic rhinitis
1 finding from 1 review
Significant adverse event: epistaxis · adults and children > 12 with non‐allergic rhinitis
Intranasal corticosteroids probably leads to higher significant adverse event: epistaxis compared with placebo (moderate certainty).
1 finding from 1 review
Disease‐specific health‐related quality of life Short Form 12 (SF‐12v2) (range 0 to 800) · adults and children > 12 with non‐allergic rhinitis
1 finding from 1 review
Health outcomes Peak expiratory flow readings (higher readings indicate better peak flow) · adults and children > 12 with non‐allergic rhinitis
It is very uncertain whether intranasal corticosteroids changes objective measurement of airflow: peak flow rate (expiratory) compared with placebo (very low certainty).
1 finding from 1 review
Other adverse events · adults and children > 12 with non‐allergic rhinitis
Intranasal corticosteroids showed no clear difference in other adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in vertigo frequency · Ménière’s disease
Intratympanic corticosteroids showed no clear difference in improvement in vertigo frequency compared with placebo/no treatment (low certainty).
2 findings from 1 review
Change in vertigo (global score) · Ménière’s disease
1 finding from 1 review
Change in vertigo frequency · Ménière’s disease
3 findings from 1 review
no estimate extracted
3 studies · 472 participants
Low
no estimate extracted
1 study · 20 participants
Very low
no estimate extracted
1 study · 18 participants
Very low
Serious adverse events · Ménière’s disease
It is very uncertain whether intratympanic corticosteroids changes serious adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review